ATE548045T1 - Vakzine in augentropfenform enthaltend copolymer 1 für die therapeutische immunisierung - Google Patents
Vakzine in augentropfenform enthaltend copolymer 1 für die therapeutische immunisierungInfo
- Publication number
- ATE548045T1 ATE548045T1 AT04700289T AT04700289T ATE548045T1 AT E548045 T1 ATE548045 T1 AT E548045T1 AT 04700289 T AT04700289 T AT 04700289T AT 04700289 T AT04700289 T AT 04700289T AT E548045 T1 ATE548045 T1 AT E548045T1
- Authority
- AT
- Austria
- Prior art keywords
- cns
- copolymer
- vaccine
- pns
- injury
- Prior art date
Links
- 229920001577 copolymer Polymers 0.000 title abstract 4
- 239000003889 eye drop Substances 0.000 title abstract 2
- 230000003053 immunization Effects 0.000 title abstract 2
- 238000002649 immunization Methods 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 229940012356 eye drops Drugs 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 4
- 208000027418 Wounds and injury Diseases 0.000 abstract 3
- 230000006378 damage Effects 0.000 abstract 3
- 208000014674 injury Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43831003P | 2003-01-07 | 2003-01-07 | |
| PCT/IL2004/000006 WO2004060265A2 (en) | 2003-01-07 | 2004-01-06 | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE548045T1 true ATE548045T1 (de) | 2012-03-15 |
Family
ID=32713312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04700289T ATE548045T1 (de) | 2003-01-07 | 2004-01-06 | Vakzine in augentropfenform enthaltend copolymer 1 für die therapeutische immunisierung |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20070248569A1 (https=) |
| EP (1) | EP1583506B1 (https=) |
| JP (1) | JP5291878B2 (https=) |
| CN (2) | CN102580069B (https=) |
| AT (1) | ATE548045T1 (https=) |
| AU (1) | AU2004203772B2 (https=) |
| CA (1) | CA2512735C (https=) |
| ES (1) | ES2386435T3 (https=) |
| IL (1) | IL169552A (https=) |
| MX (1) | MXPA05007329A (https=) |
| WO (1) | WO2004060265A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007264682B2 (en) * | 2006-06-28 | 2012-09-06 | Yeda Research & Development Co. Ltd | Method of treatment of age-related macular degeneration |
| WO2009040814A1 (en) | 2007-09-24 | 2009-04-02 | Hadasit Medical Research Services & Development Ltd | Use of copolymer 1 for treatment of muscular dystrophy |
| EP2326342B1 (en) | 2008-08-15 | 2021-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using interferon gamma to absorb fluid from the subretinal space |
| US11673914B2 (en) | 2009-11-10 | 2023-06-13 | Allegro Pharmaceuticals, LLC | Peptide therapies for reduction of macular thickening |
| MX346362B (es) | 2009-11-10 | 2017-03-15 | Allegro Pharmaceuticals Inc * | Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd. |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| WO2012143924A1 (en) | 2011-04-21 | 2012-10-26 | Mapi Pharma Ltd. | Random pentapolymer for treatment of autoimmune diseases |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| WO2015038891A2 (en) * | 2013-09-13 | 2015-03-19 | The Penn State Research Foundation | Functional peptide analogs of pedf |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| CN106491614A (zh) * | 2016-12-06 | 2017-03-15 | 郑州郑先医药科技有限公司 | 一种用于治疗脊髓损伤的西药组合及用途 |
| EP3570867A4 (en) * | 2017-01-19 | 2020-12-23 | Allegro Pharmaceuticals, LLC | THERAPEUTIC PEPTIDES AND NEUROPROTECTORS |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| US11692029B2 (en) | 2018-03-05 | 2023-07-04 | The Schepens Eye Research Institute, Inc. | Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors |
| US20230181458A1 (en) * | 2020-04-30 | 2023-06-15 | Jeffrey E. Koziol | Micro dosing of viral vaccines |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE147633T1 (de) | 1988-10-27 | 1997-02-15 | Univ Minnesota | Immunhilfsmittel aus liposome enthaltend lymphokin il -2 |
| ZA93216B (en) | 1992-01-17 | 1993-08-18 | Solvay Animal Health Inc | Vaccine containing acemannan as an adjuvant. |
| US5571515A (en) * | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| US6153182A (en) * | 1997-12-19 | 2000-11-28 | Uab Research Foundation | Lymphotactin as an adjuvant |
| EP1054880A1 (en) * | 1998-02-13 | 2000-11-29 | Autoimmune, Inc. | TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES |
| US6616925B1 (en) * | 1998-04-02 | 2003-09-09 | I.D.M. Immuno-Designed Molecules | Combined preparation for the treatment of neoplasic diseases or of infectious diseases |
| CA2361377C (en) * | 1999-02-05 | 2009-02-03 | Alk-Abello A/S | Novel mucosal delivery system |
| IL148247A0 (en) * | 1999-08-24 | 2002-09-12 | Teva Pharma | A vaccine composition and method of using the same |
| JP4328050B2 (ja) | 2000-01-20 | 2009-09-09 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用 |
| EP1294390B1 (en) * | 2000-06-07 | 2006-01-04 | YEDA RESEARCH AND DEVELOPMENT CO., Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity |
| US7351686B2 (en) | 2001-12-06 | 2008-04-01 | Yeda Research And Development Co. Ltd. | Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| WO2005030955A1 (ja) | 2003-09-29 | 2005-04-07 | Chugai Seiyaku Kabushiki Kaisha | Nk細胞に発現するタンパク質 |
| JP4501562B2 (ja) | 2004-07-09 | 2010-07-14 | 旭硝子株式会社 | 積層膜付き基材およびその製造方法 |
-
2004
- 2004-01-06 ES ES04700289T patent/ES2386435T3/es not_active Expired - Lifetime
- 2004-01-06 CA CA2512735A patent/CA2512735C/en not_active Expired - Fee Related
- 2004-01-06 MX MXPA05007329A patent/MXPA05007329A/es active IP Right Grant
- 2004-01-06 WO PCT/IL2004/000006 patent/WO2004060265A2/en not_active Ceased
- 2004-01-06 CN CN201110438909.1A patent/CN102580069B/zh not_active Expired - Fee Related
- 2004-01-06 US US10/541,492 patent/US20070248569A1/en not_active Abandoned
- 2004-01-06 JP JP2006500369A patent/JP5291878B2/ja not_active Expired - Fee Related
- 2004-01-06 EP EP04700289A patent/EP1583506B1/en not_active Expired - Lifetime
- 2004-01-06 AU AU2004203772A patent/AU2004203772B2/en not_active Ceased
- 2004-01-06 AT AT04700289T patent/ATE548045T1/de active
- 2004-01-06 CN CNA2004800062290A patent/CN1758922A/zh active Pending
-
2005
- 2005-07-06 IL IL169552A patent/IL169552A/en active IP Right Grant
-
2009
- 2009-05-07 US US12/437,167 patent/US8895501B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2512735C (en) | 2016-03-08 |
| WO2004060265A2 (en) | 2004-07-22 |
| AU2004203772A1 (en) | 2004-07-22 |
| CN102580069B (zh) | 2015-09-30 |
| WO2004060265A3 (en) | 2005-09-22 |
| AU2004203772B2 (en) | 2009-07-16 |
| US8895501B2 (en) | 2014-11-25 |
| EP1583506A4 (en) | 2009-01-07 |
| CN1758922A (zh) | 2006-04-12 |
| MXPA05007329A (es) | 2005-09-30 |
| ES2386435T3 (es) | 2012-08-21 |
| EP1583506B1 (en) | 2012-03-07 |
| EP1583506A2 (en) | 2005-10-12 |
| CA2512735A1 (en) | 2004-07-22 |
| US20090214470A1 (en) | 2009-08-27 |
| IL169552A (en) | 2012-05-31 |
| JP2006515870A (ja) | 2006-06-08 |
| JP5291878B2 (ja) | 2013-09-18 |
| HK1084034A1 (en) | 2006-07-21 |
| US20070248569A1 (en) | 2007-10-25 |
| CN102580069A (zh) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE548045T1 (de) | Vakzine in augentropfenform enthaltend copolymer 1 für die therapeutische immunisierung | |
| CY1123341T1 (el) | Μη επιλεκτικο καναλι κατιοντων στα νευρωνικα κυτταρα και ενωσεις που μπλοκαρουν το καναλι για χρηση στη θεραπευτικη αντιμετωπιση της εγκεφαλικης εξοιδησης | |
| CY1123734T1 (el) | Καταστολη συμπληρωματος για βελτιωμενη αναγεννηση νευρου | |
| DE60229639D1 (de) | Verwendung von poly-glu, tyr zur neuroprotektiven therapie des zns oder pns | |
| TW200509958A (en) | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | |
| IL150801A0 (en) | The use of copolymer 1 and related peptides and polypeptides for protecting central nervous system cells from glutamate toxicity | |
| ES2149888T3 (es) | 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias. | |
| TR200001795T2 (tr) | 1-İkameli-1-Aminometil-sikloalkan türevleri (=Gabapentin analogları), bunların hazırlanması ve nörolojik bozuklukların tedavisinde kullanımı. | |
| ATE515288T1 (de) | Carboxy-amido-triazole zur lokalisierten behandlung von augenerkrankungen | |
| HUP0300841A2 (hu) | Agonista aktivitású anti-trkC monoklonális antitestek | |
| IL159300A0 (en) | Prodrugs of gaba analogs, compositions and uses thereof | |
| EP1463531A4 (en) | PROCESS FOR INHIBITING OKULAR PROCESSES | |
| WO2002036829A3 (en) | Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries | |
| PT932613E (pt) | Expressao de bloqueio de factoes de virulencia em s. aureus | |
| BRPI0411864A (pt) | combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| MX2025006740A (es) | Composiciones farmacéuticas que contienen una de piperidinil-metil-purina amina y su uso en el tratamiento de enfermedades y afecciones | |
| ATE381533T1 (de) | Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung | |
| WO2003105750A3 (en) | ANTIGEN PRESENTER CELLS FOR NEUROPROTECTION AND NERVOUS REGENERATION | |
| AU5945301A (en) | Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis | |
| BRPI0507959A (pt) | uso de inibidores e moduladores de tweak para o tratamento de condições neurológicas | |
| WO2004060266A3 (en) | Eye-drop vaccine containing copolymer poly-ye for therapeutic immunization | |
| ATE428470T1 (de) | Heilmittel zur behandlung von erkrankungen des sehnervs | |
| UA87982C2 (ru) | Способ лечения или предотвращения расстройств центральной нервной системы производными 1-ар(алк)-4-пиперидиноимидазолин-2-она, фармацевтическая композиция | |
| WO2006047544A3 (en) | Compositions and methods for treating alzheimer’s disease and related disorders and promoting a healthy nervous system | |
| WO2002099069A3 (en) | Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule |